168 results about "Cell subpopulations" patented technology

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The invention discloses application of T cell subgroups in preparation of a kit for evaluating B cell depletion therapy and application of the T cell subgroups in preparation of the kit for evaluating B cell depletion therapy, the T cell subgroups comprise one or more of CD4 + TCM, CD4 + TEM, CD8 + TCM, CD8 + TEM, CD20 dimCD4 + TCM, CD20 dimCD4 + TCM, CD20 dimCD8 + TEM, Th17.1, Th17, Th2, CD4 + TCMTh17.1, CD4 + TEMTh17 and CD4 + TEMTh2, and the T cell subgroups comprise one or more of CD4 + TCMTh17, CD4 + TEMTh17 and CD4 + TEMTh2.

To provide a cell proliferation system, proliferation method, control method, and culture medium bag capable of proliferating various adherent cells and suspension cells. [Solution] Cells are grown in a bioreactor and activated by an activator (e.g., a soluble activator complex). The nutrient supply and gas exchange functions of an automated closed cell proliferation system make it possible to seed at, for example, a low seeding density. By manipulating the parameters of the cell growth environment, cells are placed in specific locations within the bioreactor for efficient exchange of nutrients and gases. System parameters are adjusted to shear any cell colonies that may form during the proliferation phase. Metabolic concentrations are controlled to improve cell growth and viability. Cell retention within the bioreactor is controlled. In some embodiments, the cells include T cells. In other embodiments, the cells include a T cell subpopulation, for example, regulatory T cells (Tregs).

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

The invention provides a lung adenocarcinoma immune cell subset network marker screening method. According to the lung adenocarcinoma immune cell subset network marker screening method, a lung adenocarcinoma immune cell subset network marker screening model with specificity and accuracy is constructed, and a network marker capable of accurately representing immune cell subset characteristics is screened out; meanwhile, by establishing a high-interpretability cell classification model based on the network markers and adopting the relevance between the network markers and cell classification results, the cell classification performance is improved, and effective and reliable verification of the network markers is achieved. Finally, a lung adenocarcinoma immune cell subset spatial relationship analysis algorithm based on the network marker regulatory relationship is constructed, the limitation of a high-cost spatial imaging technology is broken through, the correlation between the regulatory relationship between the network markers and immune cell spatial distribution is disclosed, and clues are provided for understanding a cell interaction mechanism in a tumor microenvironment.

Methods are disclosed for adding adapters to fragmented nucleic acids for next generation sequencing, including providing numerical codes based on variable adapter molecular barcode lengths on both sides of the fragmented nucleic acids and identifying reads from the same fragment based on both barcodes. The methods and products allow for the amplification of the fragmented nucleic acids when there is a low yield of isolated fragmented nucleic acids and also for efficient and reliable detection of low-frequency mutations including in subpopulations of cells within a subject.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The invention provides a universal UCMSC and a construction method and application thereof.The construction method includes the steps that a UCMSC specific lipid mixture containing ionizable lipid, auxiliary lipid, a stabilizer and cholesterol is prepared, the UCMSC specific lipid mixture is mixed with a nucleic acid solution containing CRISPRoff mRNA and a targeted B2M gene super enhancer sgRNA, and UCMSC specific LNP is prepared; the optimal universal UCMSC disclosed by the invention is constructed by transfecting P0-generation UCMSC with UCMSC specific LNP and screening a cell subset with low expression of HLA-I, the problems that existing universal cell construction depends on a virus or an electrotransfection system and genome change and immunological rejection exist are solved, and the optimal universal UCMSC has the effects of continuously and stably low immunogenicity, effectively avoiding immunological rejection and being free of permanent genome change. The construction method provided by the invention is safe and reliable, is simple and convenient to operate, improves the clinical accessibility of UCMSC cell therapy, reduces the burden of patients, and has a wide application prospect.

The invention belongs to the field of immunotoxicology, and particularly relates to a method for immunotyping bone marrow cells by flow cytometry. The flow cytometry immune typing method for bone marrow cells comprises the following steps: collecting macaca fascicularis bone marrow fluid, and preparing the macaca fascicularis bone marrow fluid into single-cell suspension; dyeing the obtained cells by using an antibody combination containing a plurality of fluorescent labels; then, a flow cytometer is used for collecting cell fluorescence signals, a standardized gate setting strategy is executed, and based on collected data, the percentage of each cell subset in CD45 + living white blood cells is calculated to complete immune typing. According to the flow cytometry immune typing method for the bone marrow cells, the problems of low efficiency, low repeatability, low sensitivity and poor specificity of related technologies are solved, and more accurate and reliable data support is provided for early discovery, risk assessment and mechanism research of drug immunotoxicity.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

A cancer immunotherapy for treating cancers such as melanoma is presented. A method for treating cancer in a subject via administration of anti-LY6E antibody to the subject. The method can further include administering an IFNAR blockade to inhibit type-1 interferon (IFN) signaling, thereby enhancing the ant-tumoral cytotoxic activity of T cells. The IFNAR can include anti-IFNα. The method can also include administering anti-PD1 antibody prior to, commensurate, or after treatment with anti-LY6E. A composition for treating cancer and modulating immune responses in a subject is also included. The composition can include, among other things, the anti-LY6E antibody, the IFNAR blockade, and anti-PD1. The composition and method also present a mechanism to modulate immune response in a subject by preventing upregulation of a Ly6ahigh T-cell subpopulation in response to a stimulus such as cancer, UVB, or interferons.

The application provides an analysis method, device and equipment based on single-cell transcriptome sequencing data, which comprises the following steps: performing quality control, downstream analysis and visual display on single-cell transcriptome sequencing expression quantitative data, performing cell filtering by using Grubbs test method to obtain effective single-cell transcriptome sequencing quantitative data, performing initialization clustering analysis on the data to obtain single-cell subgroup classification results; performing screening on the single-cell subgroup classification results to obtain target single-cell subgroups, and performing re-clustering analysis to obtain single-cell sub-subgroup classification results; performing significant difference gene screening analysis on the single-cell transcriptome sequencing quantitative data between single-cell subgroups; and performing regression analysis based on characteristic genes of cell cycles to predict cell division periods corresponding to different cell types. The application effectively solves the technical complex problems of existing single-cell transcriptome sequencing quantitative data analysis, makes data analysis more simple and reliable, and reduces the difficulty of data analysis.

The application belongs to the technical field of medical biological detection, and particularly relates to a construction method of a cancer drug efficacy prediction model, a molecular marker for evaluating the prognosis of intrahepatic cholangiocarcinoma obtained by the construction method, and application of the molecular marker in preparation of a reagent or kit for evaluating the prognosis of intrahepatic cholangiocarcinoma. The application provides a construction method of a cancer drug efficacy prediction model, and uses the construction method to evaluate the drug efficacy prediction of intrahepatic cholangiocarcinoma. The method can analyze the cell and transcriptome characteristic differences in the tumor environment of different efficacy patients in a high-throughput and high-resolution manner by capturing and transcriptome sequencing of a large number of cells in the tumor environment of different patients, so as to establish the correlation between the proportion of specific cell subgroups in the tumor before treatment and the efficacy of the patient.

The invention discloses a method for predicting the curative effect of triple negative breast cancer immunotherapy by spatially quantizing CD39 + CD103 + CD8 + T cells, and relates to the technical field of biology.The method comprises the following specific steps that S1, an FFPE tumor tissue sample of a TNBC subject before immunotherapy is obtained, and a continuous section with the thickness of 3-5 microns is prepared and attached to a positive charge glass slide; s2, staining the section by using a combination containing CD8 / CD103 / CD39 / Pan-CK antibodies through a TSA sequential staining method, and then re-staining cell nucleuses by using DAPI; according to the method, spatial quantitative analysis is performed on a specific CD39 + CD103 + CD8 + T cell subset, a percentage index of target cells in CD8 + T cells and an average distance index of the target cells and nearest Pan-CK positive cells in a cancer nest region are set, and the target cells are determined according to comparison between the two indexes and a preset threshold value. According to the method, whether a subject is a potential benefit crowd treated by an anti-PD-1 / PD-L1 immune checkpoint inhibitor or not is accurately judged, a standardized technical means is provided for clinically screening the potential benefit crowd for immunotherapy, the accuracy and effectiveness of triple-negative breast cancer immunotherapy are effectively improved, and invalid treatment is reduced.

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

This application relates to the field of biotechnology, specifically disclosing the application of immune cell subsets in the preparation of detection products for assessing the efficacy of neoadjuvant therapy and the risk of recurrence and metastasis in breast cancer. The detection method described in this application is non-invasive and convenient, requiring only peripheral blood, and is easy to repeat sampling and dynamic monitoring. This application also provides a predictive model for the efficacy of neoadjuvant therapy in breast cancer, and a predictive model for the risk of recurrence and metastasis in breast cancer treated with neoadjuvant therapy. The constructed predictive model has a high AUC value (0.82-0.87), and good sensitivity and specificity. Furthermore, through regular postoperative monitoring, abnormal dynamic changes in immune cell subsets can be detected, potentially indicating signs of recurrence earlier than imaging and traditional tumor markers. This helps identify advantageous populations before treatment and high-risk populations after treatment, enabling optimization of treatment plans and individualized adjustment of follow-up density.

The invention discloses an identification kit and an identification system for a pathogenic T cell subset of IgA nephropathy, and belongs to the technical field of nephropathy detection.According to the identification kit, the identification of the pathogenic T cell subset in peripheral blood of the IgA nephropathy is realized by adopting a fluorescent dye labeled antibody combination, and the antibody combination comprises a CD4 fluorescent antibody, a CD103 fluorescent antibody and an ITGB1 fluorescent antibody. The antibody combination designed by the invention can detect a pathogenic T cell subset in peripheral blood of IgA nephropathy, the T cell subset is in negative correlation with a renal function index eGFR, is in positive correlation with severity of E lesion and T lesion in IgA nephropathy kidney pathological injury oxford typing, and can be used as a significant predictive factor for reduction of eGFR and severity of E lesion and T lesion. The method has an important guiding value for real-time monitoring and prognosis prediction of the IgAN, and opens up a new view for clinical management of the IgAN.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

The application discloses a method and device for identifying a selective polyadenylation cell subpopulation, an equipment and a readable storage medium, and relates to the technical field of cell subpopulation identification. The method comprises the following steps: obtaining a selective polyadenylation expression count matrix containing a plurality of spots in spatial transcriptome data, spatial coordinate information of each spot, and a phenotype label of each spot; constructing a spatial adjacency graph of each spot based on the spatial coordinate information; training a graph attention network model by taking the selective polyadenylation expression count matrix and the spatial adjacency graph as input and taking the phenotype label as a supervision signal until the graph attention network model converges; predicting the confidence of each spot based on the graph attention network model; and taking each spot with a confidence higher than a preset confidence threshold as the selective polyadenylation cell subpopulation. The method increases the identification accuracy of the selective polyadenylation cell subpopulation.

The application relates to the technical field of stem cells, in particular to a cell subpopulation and application thereof. ‑ The application discloses a mesenchymal stem cell with stronger anti-inflammatory effect and weaker pro-inflammatory potential, which can avoid treatment resistance and promote improvement of treatment effect when applied to treatment of acute pneumonia mice, and has good clinical application value.

Provided is a peripheral blood biomarker for evaluating the antitumor immune effect of radiation therapy. Also provided is a method in which the composition of cell subpopulation in a sample obtained from a subject is used as an index for immune activation in the subject caused by a radiation therapy. By comparing, with a reference, the amount of CD4+ T cell subpopulation that correlates with dendritic cell stimulation in an antitumor immune response or the amount of dendritic cell subpopulation that correlates with the dendritic cell stimulation in an antitumor immune response, the presence or absence of, and / or the magnitude of, immune activation occurring in the subject as a result of a radiation therapy can be determined.

The invention relates to the field of biomedical detection, and particularly discloses a kit for detecting chromosome alloploid necrotic cells and application thereof, the kit comprises a metabolism tracer, a lactic acid specific binding probe connected with a detectable marker, a membrane-impermeable nucleic acid dye and a DNA metal mutual embedding agent; the use method comprises the following steps: co-incubating a to-be-detected sample and the metabolic tracer agent to enable cells to generate labeled lactic acid; sequentially contacting with a lactic acid probe, a membrane-impermeable nucleic acid dye and a DNA metal mutual embedding agent; and finally analyzing the cell state by detecting each signal. According to the method, the metabolic activity, the cell dead and living state and the DNA ploidy are synchronously detected on the single cell level, the special cell subpopulation with high glycolytic activity, necrosis characteristics and chromosome heteroploidy can be accurately recognized, and the technical problem that multi-dimensional cell information is difficult to integrate and analyze is solved; the kit has important application value in cancer diagnosis, prognosis evaluation, curative effect monitoring and drug screening.

The invention provides a determination method of signal channels of a cell subset and a cell model, a prescription efficacy prediction method and a related device, and relates to the technical field of traditional Chinese medicines. The method comprises the following steps: performing low-depth single cell transcriptome sequencing and cell grouping and annotation analysis on a disease sample and a normal control sample, screening cell subgroups of which the quantity proportion is remarkably changed in the disease sample, and performing gene expression data aggregation analysis and signal path enrichment analysis, thereby obtaining the disorder signal path of the disease-related cell subgroups. Based on the corresponding relation between the disease-related cell subpopulation and the cell model of the traditional Chinese medicine effect, the cell model and the imbalance signal channel for predicting the efficacy of the prescription are determined, and applications such as quantitative prediction of the efficacy of the prescription with the reversal of the disease signal channel as the core are further developed.

A method for identifying cell subpopulations associated with disease phenotypes, belonging to the biomedical field. To identify cell subpopulations associated with disease phenotypes, this invention collects single-cell RNA sequencing data of the disease to obtain a single-cell expression matrix, collects the bulk expression matrix of the disease and corresponding phenotypic tags, and downloads human protein-protein interaction data to construct a protein-protein interaction network; extracts gene signature features of cells and samples and maps them to the protein-protein interaction network to form corresponding cell modules and sample modules; calculates the distance between each cell module and each sample module, and determines a set of multiple sample modules as the sample module set of the disease phenotype; calculates the distance between cell modules and the sample module set of the disease phenotype; creates a background distance distribution to evaluate the statistical significance of the distance between cell modules and the sample module set of the disease phenotype, and identifies cells whose distance to the sample module set of the disease phenotype is significantly smaller than the background distance distribution.

The invention provides a synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability and a separation method, an identification method and application thereof, the cell surface of the synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability simultaneously expresses CDH13 and CD90, and the expression of NOTCH3 is deleted or the expression level of NOTCH3 is lower than a preset threshold value. The synovial stem cell subgroup with the spontaneous chondrogenic differentiation capacity is obtained and can be spontaneously differentiated into chondrocytes under the basic culture condition without adding growth factors, and better seed cells are provided for articular cartilage injury repair; the problems of inaccurate cartilage regeneration seed cell source, tedious induction steps and the like in the prior art are solved.